<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1159</ReferenceId>
        <DateLastUpdated>2018-09-17-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15470058</PubmedId>
            <Abstract>Virus-specific CD8 T cells after clearance of infection reduce their number in lymphoid organs by apoptotic death and by migration into peripheral tissues. During and after infection, many lymphocytic choriomeningitis virus (LCMV)-specific CD8 T cells in lymphoid but not peripheral tissues are in a preapoptotic state, as detected by the early apoptosis marker annexin V. In this report, we investigated the significance of this preapoptotic state and how it may be influenced by viral epitope specificity. Stimulation with anti-CD3 or IL-2 in vitro postponed DNA fragmentation in annexin V+ cells, but adoptive transfer studies in vivo showed that this preapoptotic phenotype precluded the development of functional memory. CD8 T cells specific to LCMV epitopes NP396 and gp33 differed in their preapoptotic state, with NP396-specific T cells binding more annexin V than gp33-specific T cells. These epitope- and tissue-dependent differences were seen in primary, memory, and secondary responses and in mice receiving different displays of Ag by infection with LCMV strains of different tropisms or by infection with vaccinia virus recombinants expressing LCMV proteins. Thus, the epitope-dependent differences in apoptosis were independent of virus tropisms, duration of Ag exposure, and competition within APCs, and were an intrinsic property of the epitope. The tissue-dependent and epitope-dependent preapoptotic state correlated with reduced expression of IL-7Ralpha.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>5138-47</ArticlePages>
            <ArticleTitle>Preapoptotic phenotype of viral epitope-specific CD8 T cells precludes memory development and is an intrinsic property of the epitope.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Xiaoting Z</ForeName>
                </Author>
                <Author>
                    <LastName>Brehm</LastName>
                    <ForeName>Michael A</ForeName>
                </Author>
                <Author>
                    <LastName>Welsh</LastName>
                    <ForeName>Raymond M</ForeName>
                </Author>
            </Authors>
            <Affiliations>Program in Immunology and Virology, Department of Pathology, University of Massachusetts Medical School, Worcester 01655, USA.</Affiliations>
            <ArticleChemicalList>Annexin A5;Antigens, Viral;CD3 Complex;Epitopes, T-Lymphocyte;Glycoproteins;Interleukin-2;Nucleocapsid Proteins;Nucleoproteins;Peptide Fragments;Receptors, Interleukin-7;Viral Core Proteins;Viral Proteins;glycoprotein peptide 33-41, Lymphocytic choriomeningitis virus;interleukin-7 receptor, alpha chain;Interferon-gamma</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Annexin A5(analysis); Antigens, Viral(immunology); Apoptosis; CD3 Complex(immunology); CD8-Positive T-Lymphocytes(immunology); DNA Fragmentation; Epitopes, T-Lymphocyte; Glycoproteins(immunology); Immunologic Memory; Immunophenotyping; Interferon-gamma(biosynthesis); Interleukin-2(pharmacology); Lymphocytic Choriomeningitis(immunology); Lymphocytic choriomeningitis virus(immunology); Male; Mice; Mice, Inbred C57BL; Nucleocapsid Proteins; Nucleoproteins(immunology); Organ Specificity; Peptide Fragments(immunology); Receptors, Interleukin-7(analysis); Viral Core Proteins(immunology); Viral Proteins(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>173</Volume>
                <Issue>8</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP396-404</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FQPQNGQFI</LinearSequence>
                        <StartingPosition>396</StartingPosition>
                        <EndingPosition>404</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09992.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>P. 5139</LocationOfData>
                <EpitopeId>17516</EpitopeId>
                <ReferenceStartingPosition>396</ReferenceStartingPosition>
                <ReferenceEndingPosition>404</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1B, 5, 6, 7, and 8</LocationOfData>
                        <TCellId>1267718</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1dose of 5 x 10&lt;sup&gt;4&lt;/sup&gt; PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymphocytes were analyzed 9 days after inoculation with LCMV strain Armstrong or its clone 13 variant.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP396-404</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FQPQNGQFI</LinearSequence>
                                        <StartingPosition>396</StartingPosition>
                                        <EndingPosition>404</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Annexin V staining was used as a marker of preapoptotic cells. The percent of annexin V&lt;sup&gt;+&lt;/sup&gt; NP396-specific T cells was greater in lymphoid than nonlymphoid tissue. NP396 dimer&lt;sup&gt;+&lt;/sup&gt; cells exhibited more annexin V&lt;sup&gt;+&lt;/sup&gt; cells than gp33 dimer&lt;sup&gt;+&lt;/sup&gt; cells during infection, suggesting that T cells specific to different epitopes have different sensitivities to apoptosis. The higher level of annexin V binding correlates with a lower level of IL-7RÎ± expression and greater attrition of epitope-specific T cells 100 days postinfection. Similar observations were obtained using the highly disseminating clone 13 LCMV variant or in mice coinfected with vaccinia virus recombinants expressing  either LCMV-NP or LCMV-gp.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>gp33-41</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KAVYNFATC</LinearSequence>
                        <StartingPosition>33</StartingPosition>
                        <EndingPosition>41</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>P. 5139</LocationOfData>
                <EpitopeId>30001</EpitopeId>
                <ReferenceStartingPosition>33</ReferenceStartingPosition>
                <ReferenceEndingPosition>41</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1B, 5, 6,7, and 8</LocationOfData>
                        <TCellId>1267719</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1dose of 5 x 10&lt;sup&gt;4&lt;/sup&gt; PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymphocytes were analyzed 9 days after inoculation with LCMV strain Armstrong or its clone 13 variant.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>gp33-41</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KAVYNFATC</LinearSequence>
                                        <StartingPosition>33</StartingPosition>
                                        <EndingPosition>41</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Annexin V staining was used as a marker of preapoptotic cells. The percent of annexin V&lt;sup&gt;+&lt;/sup&gt; gp33-specific T cells was greater in lymphoid than nonlymphoid tissue. Gp33 dimer&lt;sup&gt;+&lt;/sup&gt; cells exhibited less annexin V&lt;sup&gt;+&lt;/sup&gt; cells than NP396 dimer&lt;sup&gt;+&lt;/sup&gt; cells, suggesting that T cells specific to different epitopes have different sensitivities to apoptosis. The lower level of annexin V binding correlates with a higher level of IL-7RÎ± expression and less attrition of epitope-specific T cells 100 days postinfection. Similar observations were obtained using the highly disseminating clone 13 LCMV variant or in mice coinfected with vaccinia virus recombinants expressing  either LCMV-NP or LCMV-gp. Adoptive transfer experiments established that annexin V-positive and -negative gp33-specific T cells were functional in IFNÎ³ production assays.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

